Sabby Management, LLC Galectin Therapeutics Inc Transaction History

Sabby Management, LLC

  • $130,000
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018
SELL
$3.68 - $6.93 $51,626 - $97,220
-14,029 Closed
0 $0
Q2 2018

Aug 14, 2018
SELL
$3.16 - $9.16 $408,812 - $1.19 Million
-129,371 Reduced 90.22%
14,029 $89,000
Q1 2018

May 15, 2018
BUY
$3.78 - $5.97 $542,052 - $856,098
143,400 New
143,400 $680,000

Others Institutions Holding GALT

# of Institutions
90
Shares Held
9.57M
Call Options Held
1.16M
Put Options Held
1.98M
View Full List

About GALECTIN THERAPEUTICS INC

GALT Quotes by TradingView
  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $162M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Sabby Management, LLC Portfolio

Follow Sabby Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sabby Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email